Day: November 16, 2019

AG10 was Well Tolerated with Median 65 Weeks Follow-up since Phase 2 InitiationRates of All-Cause Mortality (Including Either Death or Cardiac Transplantation, 8.5%) and Cardiovascular Hospitalization (25.5%) Observed in Exploratory Analysis Were Lower than Rates Observed in Placebo-treated Participants in the ATTR-ACT StudyNear-complete Stabilization of TTR Maintained in Participants Throughout Duration of StudySerum TTR levels, a Prognostic Indicator of Survival in ATTR-CM Patients, Were Elevated and Maintained in the Normal Range Throughout the Study DurationCardiac Biomarkers and Echocardiographic Parameters Were Stable Throughout Trial DurationPresentation from AHA 2019 Scientific Sessions Available on Company Websites (eidostx.com and bridgebio.com)  SAN FRANCISCO, Nov. 16, 2019 (GLOBE NEWSWIRE) — Correction updates the increase...

AG10 was Well Tolerated with Median 65 Weeks Follow-up since Phase 2 InitiationRates of All-Cause Mortality (Including Either Death or Cardiac Transplantation, 8.5%) and Cardiovascular Hospitalization (25.5%) Observed in Exploratory Analysis Were Lower than Rates Observed in Placebo-treated Participants in the ATTR-ACT StudyNear-complete Stabilization of TTR Maintained in Participants Throughout Duration of StudySerum TTR levels, a Prognostic Indicator of Survival in ATTR-CM Patients, Were Elevated and Maintained in the Normal Range Throughout the Study DurationCardiac Biomarkers and Echocardiographic Parameters Were Stable Throughout Trial DurationPresentation from AHA 2019 Scientific Sessions Available on Company Websites (eidostx.com and bridgebio.com)  SAN FRANCISCO, Nov. 16, 2019 (GLOBE NEWSWIRE) — BridgeBio Pharma, Inc. (BridgeBio)...

Single administration of CLBS16 durably improves heart function and symptoms with no cell-related adverse eventsCLBS16 cell therapy shows promise as a significant advancement in treatment of Coronary Microvascular Dysfunction (CMD), a condition that disproportionately afflicts womenPHILADELPHIA, Nov. 16, 2019 (GLOBE NEWSWIRE) — Caladrius Biosciences, Inc. (Nasdaq: CLBS), a late-stage biopharmaceutical company focused on developing treatments for select cardiovascular diseases, along with researchers from Cedars-Sinai (Los Angeles), Mayo Clinic (Rochester, Minn.) and The Christ Hospital (Cincinnati), today presented results from the ESCaPE-CMD trial of Caladrius’s autologous CD34+ cell therapy, CLBS16, at the American Heart Association Scientific Sessions 2019. Data showed highly statistically significant improvement in coronary...

– Rapid resolution of both reported pain and inflammation as well as improvement in quality of life scores –– Tapering and discontinuation of corticosteroids without pericarditis recurrence – – Markedly lower annualized incidence of pericarditis episodes while on treatment – – Pivotal Phase 3 trial of rilonacept in recurrent pericarditis (RHAPSODY) enrolling; data expected in 2H 2020 –HAMILTON, Bermuda, Nov. 16, 2019 (GLOBE NEWSWIRE) — Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (“Kiniksa”), a biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutic medicines for patients with significant unmet medical need, reported final data from an open-label Phase 2 clinical trial of rilonacept, a weekly, subcutaneously-injected, recombinant fusion...

CITY OF NORTH VANCOUVER, British Columbia, Nov. 16, 2019 (GLOBE NEWSWIRE) —  Tree Canada is proud to help commemorate CN’s (TSX: CNR) (NYSE: CNI) 100th anniversary through a special Legacy Forest planting that will take place in Moodyville park this afternoon.  A gift of 100 trees has been donated to the citizens of the City of North Vancouver as part of the CN100 – A Moving Celebration. Tree Canada has partnered with CN to plant 100 trees in 8 different Canadian cities this year to honour CN’s commitment to greening communities with more cities set to receive trees in 2020.Mayor Linda Buchanan will welcome residents, CN pensioners and community members to come and plant and play. Over 300 shrubs and 100 trees will be planted throughout the park as well as a newly designed playground will be open for all to enjoy. A ceremonial...

CITY OF NORTH VANCOUVER, Colombie-Britannique, 16 nov. 2019 (GLOBE NEWSWIRE) — Arbres Canada est fier de contribuer à souligner le 100e anniversaire du CN (TSX : CNR) (NYSE : CNI) grâce à la plantation spéciale d’une forêt patrimoniale au parc Moodyville cet après-midi. Un don de 100 arbres a été fait aux citoyens de City of North Vancouver dans le cadre de la tournée CN100 – Célébration en mouvement. De concert avec le CN, Arbres Canada a planté 100 arbres dans huit villes canadiennes cette année pour rendre hommage à l’engagement du CN à promouvoir le verdissement des collectivités et à donner des arbres à davantage de villes en 2020.La mairesse Linda Buchanan accueillera les résidents, les retraités du CN et les membres de la collectivité qui viendront participer à cet événement, planter des arbres et s’amuser. Plus de 300 arbustes...

FORT WAYNE, Ind., Nov. 16, 2019 (GLOBE NEWSWIRE) — Vera Bradley, Inc. (NASDAQ: VRA; “Vera Bradley” or the “Company”), a leading American bag and luggage company and iconic lifestyle brand, today announced it designed an exclusive backpack inspired by the central character in Hulu’s original series Holly Hobbie™.  Holly Hobbie™ is an original music-driven revival of the classic, girls’ character brand which was hugely popular in the 1970’s and 80’s. Season 2, set to debut on November 22, continues to track the evolution of 14-year-old Holly Hobbie, played by Ruby Jay, a talented singer-songwriter whose open-mic nights influence her personal development as well as that of her friends, family and community. Vera Bradley collaborated with Holly Hobbie™ producers to design and develop a backpack that uniquely expresses the title character’s...

MONTREAL, Nov. 16, 2019 (GLOBE NEWSWIRE) — CN (TSX: CNR) (NYSE: CNI) said today that the Teamsters Canadian Rail Conference – Conductors, Trainpersons and Yardpersons (TCRC-CTY), which represents approximately 3,200 CN employees who work as train conductors and railyard coordinators only in Canada, has given the company a 72-hour notice of its intention to strike as of 00:01 hours Eastern Standard Time on November 19, 2019.Rob Reilly, executive vice-president and chief operating officer of CN, said: “We continue to negotiate in good faith to reach a fair agreement before the strike deadline. In the spirit of protecting the Canadian economy, we have offered the union binding arbitration and they have declined.  If a settlement cannot be reached this weekend, we will once again encourage the union leadership to accept binding arbitration...

MONTRÉAL, 16 nov. 2019 (GLOBE NEWSWIRE) — Le CN (TSX : CNR) (NYSE : CNI) a annoncé aujourd’hui que la Conférence ferroviaire de Teamsters Canada – chefs de train, agents de train et agents de triage (CFTC-CAT), qui représente environ 3 200 chefs de train et préposés aux manœuvres du CN basés seulement au Canada, lui avait remis un préavis de 72 heures lui signifiant son intention de déclencher la grève à 00h01, heure normale de l’Est, le 19 novembre 2019.Rob Reilly, vice-président exécutif et chef de l’exploitation du CN, a déclaré : « Nous continuons de négocier de bonne foi afin de parvenir à une entente équitable avant la date butoir du déclenchement de la grève. Afin de protéger l’économie canadienne, nous avons offert au Syndicat de recourir à l’arbitrage exécutoire, mais il a refusé. Si nous ne pouvons pas parvenir à un accord...

UPPSALA, SWEDEN – LIDDS AB (publ) Phase IIb clinical data from the LPC-004 prostate cancer study on LIDDS Liproca® Depot were presented today in an oral session at the 11th European Multidisciplinary Congress on Urological Cancers, EMUC19. The study met both its primary and secondary endpoints as well as demonstrated that a larger proportion of intermediate risk patients, which is the Liproca Depot target group, are PSA responders. The presentation can be accessed through LIDDS webpage and are also attached to this release.The phase IIb results from the LPC-004 prostate cancer study was presented as “Late Breaking News” at EMUC in Vienna on November 16, 2019 by Professor Laurence Klotz, a world leading expert in Active Surveillance of prostate cancer patients. Professor Klotz was one of the LPC-004 study investigators and is Professor at...